Biotech News

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals, Inc. (KALV)KalVista Pharmaceuticals, Inc.2026-02-25 12:00 ESTConference / presentation

FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 25, 2026-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: TD Cowen 46 th Annual Healthcare Conference on

KalVista Pharmaceuticals, Inc.

Hereditary Angioedema Company KalVista Pharmaceuticals develops and commercializes therapies for hereditary angioedema. Its lead franchise is based on oral inhibition of plasma kallikrein during acute attacks. EKTERLY EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks. It is...

Recent company news

KALVKalVista Pharmaceuticals, Inc.2026-06-11 12:41 EST

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

KALVKalVista Pharmaceuticals, Inc.2026-05-28 11:00 EST

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

KALVKalVista Pharmaceuticals, Inc.2026-04-29 11:00 EST

Stock data

Close: 26.95 USD
Market cap: 1.43B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Related news

KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference